Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers attribute modest improvement in lung cancer patients to novel targeted therapies

Research released in the December 2009 issue of the Journal of Thoracic Oncology sought to determine whether the survival improvement among patients with metastatic lung cancer has improved over the last two decades as reported in controlled clinical trials.

2 Dec 2009

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

The constant increase in the rate of cutaneous melanoma over recent years and its resistance to anti-tumour pharmaceutical drugs has meant that the study of cutaneous melanoma is one of the greatest scientific challenges in the field of cancer. The Human Melanoma research team at the University of the Basque Country (UPV/EHU) is focusing on this study.

2 Dec 2009

Development of novel virus can lead to new therapeutic strategy to combat cancer

Ohio State University cancer researchers have developed a tumor-attacking virus that both kills brain-tumor cells and blocks the growth of new tumor blood vessels.

2 Dec 2009

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

Using routine computed tomography (CT) imaging to analyze form and structural changes to colorectal liver metastasis after bevacizumab and chemotherapy may predict overall survival, according to research from The University of Texas M. D. Anderson Cancer Center.

2 Dec 2009

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

Cancer researchers at the University of Oklahoma Health Sciences Center have found a way to turn ineffective new cancer drugs into cancer-fighters. By using their patented chemical compound, SHetA2, researchers tricked cancer cells into responding to new treatments and undergoing cell suicide.

2 Dec 2009

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

Cell Therapeutics, Inc. (CTI) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana.

2 Dec 2009

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Memgen announced today that results from its ongoing, Leukemia & Lymphoma Society co-sponsored clinical trial in chronic lymphocytic leukemia (CLL) have been selected for an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

2 Dec 2009

CRO to run CEL-SCI's upcoming Phase III clinical trial

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.

1 Dec 2009

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

1 Dec 2009

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Teva Pharmaceutical Industries Ltd., today announced the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Dec 2009

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.

1 Dec 2009

Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed

ADVENTRX Pharmaceuticals, Inc. today announced that a new, recently completed preclinical study has affirmed the bioequivalence and comparable toxicity of ANX-514 and Taxotere® (docetaxel). Shin Poong Pharmaceuticals, ADVENTRX's partner for ANX-514 in South Korea, independently conducted the study and data analysis.

1 Dec 2009

Amgen to present updated data on Nplate at the 2009 ASH meeting

Amgen Inc. today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition (Dec. 5 - 8, 2009).

1 Dec 2009

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines -produced from healthy and tumour cells from the patient him or herself- and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

1 Dec 2009

Clinical trials of personalised vaccines to fight glioblastomas

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalised vaccines —produced from healthy and tumour cells from the patient him or herself— and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumours.

30 Nov 2009

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.

30 Nov 2009

Siemens Healthcare to introduce high-end imaging systems for interventional oncological procedures at RSNA 2009

At the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from November 29 to December 3 at McCormick Place in Chicago, Siemens Healthcare will introduce its comprehensive portfolio for imaging in interventional oncology at booth #825, East Building/Lakeside Center, Hall D.

30 Nov 2009

Researchers devise new tools for typing cells from children with acute lymphatic leukemia

Researchers at Uppsala University and University Children's Hospital in Uppsala have devised powerful new tools for typing cells from children with acute lymphatic leukemia and for prediction of how children with leukemia will respond to chemotherapy.

28 Nov 2009

'Suicide gene E' reduces potent drug dosage in cancer patients

Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.

25 Nov 2009

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML).

25 Nov 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers attribute modest improvement in lung cancer patients to novel targeted therapies

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

Development of novel virus can lead to new therapeutic strategy to combat cancer

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

CRO to run CEL-SCI's upcoming Phase III clinical trial

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Bioequivalence and comparable toxicity of ADVENTRX Pharmaceuticals' ANX-514 and Taxotere affirmed

Amgen to present updated data on Nplate at the 2009 ASH meeting

University of Navarra Hospital launches clinical trials to assess the efficacy of immunotherapy treatment

Clinical trials of personalised vaccines to fight glioblastomas

Gentium announces financial results for the third quarter ended September 30, 2009

Siemens Healthcare to introduce high-end imaging systems for interventional oncological procedures at RSNA 2009

Researchers devise new tools for typing cells from children with acute lymphatic leukemia

'Suicide gene E' reduces potent drug dosage in cancer patients

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in